Therefore, MMP-7 and TIMP-2 may be useful molecular markers for evaluating prognosis in CCRCC patients and MMP-7 may be a new target for the prevention of tumor development and improvement of survival rate. Here, TIMP2 is linked to nonpapillary renal cell carcinoma.